- Home
- AVK vs ANGO Comparison
AVK vs ANGO Comparison
Compare AVK & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVK | ANGO |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.9M | 453.0M |
| IPO Year | 2003 | 2004 |
Fundamental Metrics
Financial Performance| Metric | AVK | ANGO |
|---|---|---|
| Price | $11.98 | $10.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 127.8K | ★ 246.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $291,010,000.00 |
| Revenue This Year | N/A | $9.11 |
| Revenue Next Year | N/A | $4.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $9.75 | $8.36 |
| 52 Week High | $13.10 | $13.99 |
Technical Indicators
Market Signals| Indicator | AVK | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 36.14 | 42.38 |
| Support Level | $11.58 | $10.40 |
| Resistance Level | $12.06 | $11.06 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 21.95 | 17.07 |
Price Performance
Historical ComparisonAbout AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.